Compare CNOBP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNOBP | CMMB |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | 493 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 13.8M |
| IPO Year | N/A | N/A |
| Metric | CNOBP | CMMB |
|---|---|---|
| Price | $24.18 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | N/A | ★ 95.6K |
| Earning Date | N/A | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.73 |
| 52 Week High | N/A | $9.84 |
| Indicator | CNOBP | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 32.11 |
| Support Level | $24.16 | $1.73 |
| Resistance Level | $24.25 | $2.21 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 70.87 | 23.07 |
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.